SCHEMBL38075

SCHEMBL38075

NC(=O)C(=O)I

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL60772 0.78
SCHEMBL28566412 0.74
Hydrochloric Acid SCHEMBL28638294 0.74
SCHEMBL3161687 0.73
SCHEMBL4475934 0.72 LMNA (0.62)
SCHEMBL7743262 0.72
SCHEMBL52275 0.72
SCHEMBL1668284 0.72
Bicarbonate SCHEMBL8812310 0.70
Water SCHEMBL23118545 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1188 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022240255-A1 BIODEGRADABLE STENT AND MANUFACTURING METHOD THEREFOR 전남대학교산학협력단 2022-11-17 WO claimed
WO-2021238893-A1 EFFICIENT AND EFFECTIVE TISSUE CLEARING AGENTS AND THEIR COMPOSITIONS THE CHINESE UNIVERSITY OF HONG KONG (CN) 2021-12-02 WO claimed
US-20170066828-A1 Humanized Anti-HLA-DR Antibodies IMMUNOMEDICS, INC. 2017-03-09 US claimed
US-9393325-B2 Bioabsorbable co-filler for cerebrovascular aneurysms ABBOTT CARDIOVASCULAR SYSTEMS INC. (US) 2016-07-19 US claimed
US-20160151124-A1 IMPLANTABLE MARKERS YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) 2016-06-02 US claimed
EP-3019208-A1 IMPLANTABLE MARKERS Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) 2016-05-18 EP claimed
EP-1521775-B1 MONOCLONAL ANTIBODY PAM4 AND ITS USE FOR DIAGNOSIS AND THERAPY OF PANCREATIC CANCER IMMUNOMEDICS INC (US) 2015-09-09 EP claimed
US-8986699-B2 Anti-CD74 immunoconjugates and methods of use IMMUNOMEDICS, INC. (US) 2015-03-24 US claimed
WO-2015004669-A1 IMPLANTABLE MARKERS YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) 2015-01-15 WO claimed
EP-1519958-B1 HUMANIZED MONOCLONAL ANTIBODY HPAM4 IMMUNOMEDICS INC (US) 2014-10-15 EP claimed
WO-2003103723-A2 NEUTROPHIL IMAGING METHODS IN CYCTIC FIBROSIS IMMUNOMEDICS, INC. (US) 2003-12-18 WO claimed
WO-2003097105-A1 DRUG PRE-TARGETING BY MEANS OF BI-SPECIFIC ANTIBODIES AND HAPTEN CONSTRUCTS COMPRISING A CARRIER PEPTIDE AND THE ACTIVE AGENT (S) IMMUNOMEDICS, INC. (US) 2003-11-27 WO claimed
US-20030198595-A1 Use of bi-specific antibodies for pre-targeting diagnosis and therapy IMMUNOMEDICS, INC. 2003-10-23 US claimed
US-20030148409-A1 Direct targeting binding proteins IBC PHARMACEUTICALS 2003-08-07 US claimed
WO-2003033654-A2 DIRECT TARGETING BINDING PROTEINS IMMUNOMEDICS, INC (US) 2003-04-24 WO claimed
WO-2002082041-A2 PRODUCTION AND USE OF NOVEL PEPTIDE-BASED AGENTS FOR USE WITH BI-SPECIFIC ANTIBODIES IMMUNOMEDICS, INC. (US) 2002-10-17 WO claimed
EP-0703790-B1 IODINATED PARAMAGNETIC CHELATES, AND THEIR USE AS CONTRAST AGENTS BRACCO SPA (IT) 2000-08-16 EP claimed
US-5660814-A Iodinated paramagnetic chelates, and their use as contrast agents DIBRA S.P.A. (IT) 1997-08-26 US claimed
EP-0703790-A1 IODINATED PARAMAGNETIC CHELATES, AND THEIR USE AS CONTRAST AGENTS BRACCO S.p.A. (IT) 1996-04-03 EP claimed
WO-1994027644-A1 IODINATED PARAMAGNETIC CHELATES, AND THEIR USE AS CONTRAST AGENTS BRACCO S.P.A. (IT) 1994-12-08 WO claimed